glun2d

GNE-0723 is a selective positive allosteric modulator of the NMDA receptor, with an EC50 of 21 nM for GluN2A. It can cross the blood-brain barrier (BBB) and improve outcomes in Dravet syndrome (DS) and Alzheimer's disease (AD).

GNE-5729 is a positive allosteric modulator of NMDAR with the advantage of crossing the blood-brain barrier and being orally available, with EC50 values of 37 nM, 4.7 μM and 9.5 μM for GluN2A, GluN2C and GluN2D, respectively, and can be used for the study of neurological and psychiatric disorders.

(RS)-(Tetrazol-5-yl)glycine is a potent and selective N-methyl-D-aspartate (NMDA) receptor agonist that can induce seizure models and Fos expression in mice. Its EC50 values for GluN1/GluN2D and GluN1/GluN2A are 99 nM and 1.7 μM, respectively.

UBP608 is an allosteric modulator of NMDA receptor family. It selectively inhibits GluN1/GluN2A receptors with a 23-fold selectivity compared to GluN1/GluN2D receptors.

(3S,6R)-NML is an NMDA receptor antagonist with pIC50 values of 4.8 [GluN1-GluN2A], 4.6 [GluN1-GluN2B], 5.0 [GluN1-GluN2C], and 5.0 [GluN1-GluN2D]. It is applicable in the study of depression.

YY-23 is a selective NMDAR (containing GluN2C or GluN2D) inhibitor. By inhibiting NMDARs with GluN2D on GABAergic interneurons in the prefrontal cortex, YY-23 suppresses GABAergic neurotransmission and enhances excitatory transmission. YY-23 exhibits antidepressant activity and is useful for neurological disease research.

EU 1622-240 is an allosteric modulator with a preference for GluN2B, GluN2C, and GluN2D, exhibiting EC50 values of 0.57, 0.82, and 1.1 μM, respectively. It possesses favorable physicochemical properties, along with in vitro stability and permeability.

DQP 1105 is a NMDA receptor antagonist.

NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptors potentiator.

NAB-14 is a powerful and selective chemical compound that acts as a non-competitive antagonist for GluN2C and GluN2D receptors. With an IC50 value of 580 nM for GluN1 GluN2D, NAB-14 demonstrates high potency. This compound exhibits a remarkable selectivity of more than 800-fold towards recombinant GluN2C and GluN2D when compared to GluN2A and GluN2B. Furthermore, NAB-14 possesses the ability to penetrate the blood-brain-barrier effectively [1].

TP-050 is a potent, selective NMDAR agonist that is orally active, showing EC50 values of 0.51 µM for GluN2A and 9.6 µM for GluN2D. This compound can cross the blood-brain barrier (BBB), enhancing hippocampal long-term (LTP) potentiation and neuronal signal transmission.

DQP-26, a potent negative allosteric modulator of NMDA receptors (NMDARs), exhibits IC50 values of 0.77 μM for GluN2C and 0.44 μM for GluN2D subunits, indicating potential application in research on NMDAR-associated neurological diseases [1].